Solid Tumors
Conditions
Interventions
case series:Nil
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Aged 18-75, male and female, with ECOG score of 0 or 1; 2) Subjects with head and neck tumors, lung cancer, esophageal cancer, breast cancer, ovarian cancer, cholangiocarcinoma, colorectal cancer, gastric cancer, pancreatic cancer, melanoma, bone or soft tissue sarcoma, solid tumors or suspected tumor subjects who intend to undergo pathological tissue biopsy or receive tumor surgical treatment in the near future (within 2 months); 3) The expected survival was more than 12 weeks; 4) Blood routine test, liver and kidney function meet the following standards: blood routine: WBC >= 4.0 x 10^9/L or neutrophil >= 1.5 x 10^9/:, PLT >= 100 x 10^9 / L, Hb >= 90g / L; Pt or APTT <= 1.5uln; liver and kidney function: T-Bil <= 1.5 x ULT (upper limit of normal value), ALT / AST <= 2.5uln or <= 5 x ULT (subject with liver metastasis), ALP <= 2.5uln (if bone metastasis or liver metastasis exists, ALP <= 4.5uln); BUN <= 1.5 x ULT, SCR <= 1.5 x ULT; 5) According to RECIST1.1, there was at least one measurable target lesion; 6) Women must take effective contraceptive measures during the study period and within 6 months after the end of the study (effective contraceptive measures refer to sterilization, hormone devices in children, condoms, contraceptives / pills, abstinence or partner removal of vas deferens, etc.); men should agree to use contraceptive measures during the study period and within 6 months after the end of the study period; 7) Understand and sign informed consent voluntarily with good compliance.
Exclusion criteria
Exclusion criteria: 1) The function of liver and kidney was seriously abnormal; 2) Preparation for pragnant, pregnant and lactating women; 3) Inability to lie flat for half an hour; 4) Suffering from claustrophobia or other mental disorders; 5) Other researchers considered it unsuitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUV/SUL; | — |
Countries
China
Contacts
Public ContactYang Zhi
Nuclear Medicine Department, Beijing Cancer Hospital
Outcome results
None listed